All the resolutions proposed by the Board of Directors were adopted
Paris and Boston, June 5, 2025 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, held its Combined General Meeting of June 5, 2025, which was chaired by Mr. Sacha Loiseau, Chairman of the Board of Directors and CEO.
With a quorum of 38.5%, all the resolutions proposed by the Board of Directors have been adopted. Among the main resolutions approved were the adoption of the annual and consolidated financial statements for the year ended December 31, 2024, the allocation of the 2024 net result, as well as delegations granted to the Board of Directors related to financial transactions.
Details on the vote results are available on the Company’s website.
